One of the S&P 500’s big winners for Thursday January 14 was Celgene Corp. (CELG) as the company’s stock climbed 6.41% to $107.12 on volume of 6.27 million shares.

The stock opened at $101.34 and saw an intraday low of $99.44 and an intraday high of $107.18. All told, the day saw a per-share gain of $6.45. The stock’s average daily volume of 5.31 million and 785.65 million shares outstanding. Celgene Corp. now has a 50-day SMA is $113.68 and 200-day SMA is $117.74, and it has a 52-week high of $140.72 and a 52-week low of $92.98.

Celgene Corp is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Based out of Summit, NJ, Celgene Corp. has 6,012 employees and, after today’s trading, reached a market cap of $84.16 billion. The stock’s P/E Ratio is 54. Its P/S ratio is 11.82, P/B ratio is 15.66, and P/FCF ratio is -13.3.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

DISCLOSURE:
The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer